Oct 25, 2023

News provided by Share this article Share toX PALO ALTO, Calif., Oct. 25, 2023 /PRNewswire/ -- Glooko, Inc., a global leader in chronic condition management, specializing in connected care and remote patient monitoring for diabetes and other related diseases, today announced the appointment of Enrique Conterno to its Board of Directors. Mr. Conterno is a well-known executive in the pharmaceutical industry with deep expertise in the diabetes field. He joins the board of Glooko having served most recently as the Chief Executive Officer and a member of the Board at FibroGen, Inc. Before FibroGen, Mr. Conterno was Senior Vice President for Eli Lilly and Company, serving as President of Lilly USA from January 2017, and President of Lilly Diabetes from 2009, until his retirement from Lilly in December 2019. Prior to 2009, Mr. Conterno served in various other roles for Eli Lilly and Company, including President, U.S. Operations, Vice President for the U.S. Neuroscience Business Unit, President and General Manager, Mexico, and Executive Marketing Director, Intercontinental Operations and Japan. Mr. Conterno earned a Bachelor of Science degree in Mechanical Engineering from Case Western Reserve University and a Master of Business Administration from Duke University. He is a member of the Board of Governors of the American Red Cross. "We are extremely pleased to welcome Enrique to our Board. His deep knowledge of the diabetes space and his leadership of the diabetes enterprise at Lilly will be invaluable to Glooko as we grow our connected care business in diabetes and related chronic conditions as well as our digital life sciences practice," said Russ Johannesson, CEO of Glooko. "In addition, his broad experience from his operational, marketing and growth leadership roles will help to guide our strategic vision of becoming the go-to platform for chronic care management." Mr. Conterno has deep familiarity with the global healthcare ecosystem and has overseen multiple, important major product launches in the diabetes space. His three decades of leadership and proven track record of growing revenues and businesses will further enhance Glooko's already significant global positioning in the digital life sciences marketplace. "I am delighted to join the board of Glooko during this pivotal and important time in the company's history and look forward to working with the team to grow the diabetes franchise as well as penetrate the rapidly growing adjacent areas, including obesity and cardiometabolic disease," said Mr. Conterno. "Glooko brings innovative digital health solutions to patients, providers, and clinical and pharmaceutical companies around the world. I am excited to leverage my insights to help Glooko to reach its full potential." About Glooko Glooko improves health outcomes of people with chronic conditions through its personalized, intelligent, connected care platform. Our proven technologies make lives better by revolutionizing the connection between patients and providers, driving patient engagement and adherence via digital therapeutics, and accelerating the speed of clinical trials. Glooko is globally deployed in over 30 countries and 8,000+ clinical locations. For more information, please visit glooko.com . Media Inquiries: